BioDrugs

, Volume 20, Issue 6, pp 357–362 | Cite as

Effects of Site-Specific Polyethylene Glycol Modification of Recombinant Human Granulocyte Colony-Stimulating Factor on its Biologic Activities

  • Yong Hao
  • Junhui Chen
  • Xinchang Wang
  • Haowen Zhu
  • Zhigang Rong
Short Communication

Abstract

Background

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is a long-chain cytokine that is administered to stimulate the production of white blood cells (WBCs) to reduce the risk of serious infection in immunocompromized patients. However, to achieve sustained stimulation of WBC production, rhG-CSF must be administered frequently, thus limiting its clinical use.

Methods

We conjugated rhG-CSF with linear monomethoxy-polyethylene glycol (PEG) maleimide at amino acid residue Cys17 to test our hypothesis that this could extend the in vivo half-life of rhG-CSF in blood.

Results

The mono-PEG rhG-CSF became more stable to pH, temperature, and enzyme degradation in vitro, and had granulopoietic activity that was superior to the unmodified form in vivo. The granulopoietic activity of PEG-G-CSF was 2.82-fold greater than that of unmodified G-CSF.

Conclusions

These results indicate that the thiol-specific PEGylation remarkably prolonged the half-life of rhG-CSF and represents a novel strategy to address the more clinically acceptable therapeutic application of hemopoietic growth factor.

References

  1. 1.
    Zalipsky S. Chemistry of polyethylene glycol conjugates with biologically active molecules. Adv Drag Deliver Rev 1995; 16: 157–82CrossRefGoogle Scholar
  2. 2.
    Greenwald RB, Choe YH, McGuire J, et al. Effective drug delivery by PEGylated drag conjugates. Adv Drug Deliver Rev 2003; 55: 217–50CrossRefGoogle Scholar
  3. 3.
    Greenwald RB. PEG drugs: an overview. J Control Release 2001; 74: 159–71PubMedCrossRefGoogle Scholar
  4. 4.
    Metcalf D. The hemopoietic colony stimulating factors. Amsterdam: Elsevier, 1984Google Scholar
  5. 5.
    Weite K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907–29Google Scholar
  6. 6.
    Lie AK W, Hui CH, Rawling T, et al. Granulocyte colony-stimulating factor (G-CSF) dose-dependent efficacy in peripheral blood stem cell mobilization in patients who had failed initial mobilization with chemotherapy and G-CSF. Bone Marrow Transpl 1998; 22(9): 853–7Google Scholar
  7. 7.
    Fukumasu Y, Fukumasu H, Yamamasu S, et al. Stimulation of fetal granulopoiesis by intrauterine injection of recombinant human granulocyte colony-stimulating factor into rat fetuses. Biol Neonate 1999; 75(6): 367–76PubMedCrossRefGoogle Scholar
  8. 8.
    Haithcox S, Ramnes CR, Lee H, et al. The impact of frequent injections for hematopoietic growth factor support on patients receiving chemotherapy: an observational study. BMC Nurs 2003; 2: 2PubMedCrossRefGoogle Scholar
  9. 9.
    Morstyn G, Foote M, Walker T, et al. Filgrastim (r-metHuG-CSF) in the 21st century: SD/ 01. Acta Haematol 2001; 105: 151–5PubMedCrossRefGoogle Scholar
  10. 10.
    Holmes FA, O’Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration PEG filgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002; 20: 727–31PubMedCrossRefGoogle Scholar
  11. 11.
    King DJ, Turner A, Farnsworth APH, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994; 54: 6176–85PubMedGoogle Scholar
  12. 12.
    Bishop B, Koay DC, Sartorelli AC, et al. Reengineering granulocyte colony-stimulating factor for enhanced stability. J Biol Chem 2001; 276(36): 33465–70PubMedCrossRefGoogle Scholar
  13. 13.
    Cantin AM, Woods DE, Cloutier D, et al. Polyethylene glycol conjugation at Cys232 prolongs the half-life of α1 proteinase inhibitor. Am J Respir Cell Mol Biol 2002; 27: 659–65PubMedGoogle Scholar
  14. 14.
    Roberts MJ, Bentley MD, Harris JM. Chemistry for peptide and protein PEGylation. Adv Drag Deliv Rev 2002; 54: 459–76CrossRefGoogle Scholar
  15. 15.
    Colgstone CL, Boone TC, Souza LN, et al. Disulfide and secondary structures of recombinant human granulocyte colony-stimulating factor. Arch Biochem Biophys 1989; 268: 81–92CrossRefGoogle Scholar
  16. 16.
    Kubota N, Orita T, Hattori K, et al. Structural characterization of natural and recombinant human granulocyte colony-stimulating factors. J Biochem (Tokyo) 1990; 107(3): 486–92Google Scholar
  17. 17.
    Matsuda S, Shirafuji N, Asano S. Human granulocyte colony-stimulating factor specifically binds to murine myeloblastic NFS-60 cells and activates their guanosine triphosphate binding proteins/adenylate cyclase system. Blood 1989; 74: 2343–8PubMedGoogle Scholar
  18. 18.
    Bowen S, Tare N, Inoue T, et al. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp Hematol 1999; 27: 425–32PubMedCrossRefGoogle Scholar
  19. 19.
    Kinstler OB, Brems DN, Lauren SL, et al. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharmaceut Res 1996; 13: 996–1002CrossRefGoogle Scholar
  20. 20.
    de Haan G, Ausema A, Wilkens M, et al. Efficient mobilization of haematopoietic progenitors after a single injection of pegylated recombinant human granulocyte colony-stimulating factor in mouse strains with distinct marrow-cell pool sizes. Br J Haematol 2000; 110: 638–46PubMedCrossRefGoogle Scholar
  21. 21.
    Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrags 2001; 15(7): 419–29CrossRefGoogle Scholar
  22. 22.
    Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drag Discov 2003; 2: 214–21CrossRefGoogle Scholar
  23. 23.
    Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials 2002; 22: 405–17CrossRefGoogle Scholar
  24. 24.
    Goodson RJ, Katre NV. Site-directed pegylation of recombinant interleukin-2 at its glycosylation site. Biotechnology (NY) 1990; 8: 343–6CrossRefGoogle Scholar
  25. 25.
    Kurfurst MM. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1992; 200(2): 244–8PubMedCrossRefGoogle Scholar
  26. 26.
    Johnston E, Crawford J, Blackwell S, et al. Randomized, doseescalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522–8PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Yong Hao
    • 1
  • Junhui Chen
    • 1
  • Xinchang Wang
    • 1
  • Haowen Zhu
    • 2
  • Zhigang Rong
    • 2
  1. 1.State Key Laboratory of Pharmaceutical Biotechnology, Department of BiochemistryNanjing UniversityNanjingPeople’s Republic of China
  2. 2.Biopharmaceutical Institute of Jiangsu WuzhongSuzhou, JiangsuPeople’s Republic of China

Personalised recommendations